Compare Ascendis Pharma A/S (ASND) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Morgan Stanley — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Morgan Stanley trades at $222.53 (market cap $350.60B). The key difference: Morgan Stanley is far larger — about 19.8× Ascendis Pharma A/S's market cap, and Morgan Stanley pays a 1.8% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MS | |
|---|---|---|
Market Cap | $17.74B | $350.60B |
Sector | Health | Financials |
52-Week High | $277.18 | $227.19 |
52-Week Low | $163.32 | $139.09 |
Enterprise Value | $18.11B | — |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Morgan Stanley (MS) trades at $222.28, up 0.07% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $57.6B in 2024 to $66.0B in 2025 and net income reaching $16.9B. Recent earnings beats and selection to lead Anthropic's IPO highlight operational strength. Technical indicators show support at $220 and resistance at $224, with RSI suggesting mild overbought conditions.
Outlook remains positive with 53.85% analyst buy ratings and $225.80 consensus price target. Key opportunities include wealth management expansion and AI integration, while risks involve volatile cash flows and rising debt-to-asset ratios. The stock offers potential upside but requires monitoring of financial leverage and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
